Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N1,N11-diethylnorspermine (DENSPM) is a synthetic polyamine analog and potent anticancer agent. It acts primarily by disrupting polyamine homeostasis in cells, modulating the activities of key biosynthetic enzymes such as ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC). DENSPM induces the catabolic enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT), leading to depletion of intracellular polyamines, which are essential for DNA structure, cell division, differentiation, and membrane function. This disruption can result in inhibition of tumor cell growth and proliferation. Preclinical studies have shown activity against various cancers including renal cell carcinoma, pancreatic cancer, melanoma, and lung cancer[4][7]. At low concentrations it may mimic endogenous polyamines in resistant cells; at higher concentrations it inhibits growth across multiple lines[7]. The compound is under investigation as a novel chemotherapeutic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N1,N11-diethylnorspermine.